Addition of trilaciclib to chemotherapy/ICI treatment combinations enhances CR and median OS
| Model | Treatment | Schedule | No. of animals | PR% | CR% | ORR% | OS (days) |
| MC38 | Vehicle | – | 30 | 0 | 0 | 0 | 18 |
| OP | I | 24 | 13 | 33 | 46 | 59 | |
| TOP* | I | 24 | 8 | 67 | 75 | Not reached | |
| OP | M | 13 | 0 | 15 | 15 | 44 | |
| TOP* | M | 13 | 8 | 62 | 70 | Not reached | |
| OP | IM | 14 | 7 | 36 | 43 | 52 | |
| TOP* | IM | 14 | 7 | 79 | 86 | Not reached | |
| Oxaliplatin + αPD-1 | IM | 15 | 0 | 40 | 40 | 64 | |
| Trilaciclib +oxaliplatin + αPD-1 | IM | 15 | 0 | 60 | 60 | Not reached | |
| 5-FU + αPD-L1 | IM | 14 | 0 | 29 | 29 | 39 | |
| Trilaciclib + 5-FU + αPD-L1 | IM | 14 | 0 | 50 | 50 | 76.5 | |
| CT26 | Vehicle | – | 10 | 0 | 0 | 0 | 18 |
| OP | IM | 15 | 0 | 0 | 0 | 25 | |
| TOP | IM | 15 | 7 | 13 | 20 | 39 |
Statistical significance comparing CR rate of TOP to OP within each treatment schedule was evaluated using Fisherʼs exact test.
*P≤0.05.
CR, complete response; 5-FU, 5-fluorouracil; I, induction; ICI, immune checkpoint inhibitor; IM, induction plus maintenance; M, maintenance; OP, oxaliplatin plus; ORR, objective response rate; OS, median overall survival; αPD-1, anti-programmed death-1; αPD-L1, anti-programmed death-ligand-1; PR, partial response; TOP, trilaciclib plus oxaliplatin and anti-programmed death-ligand-1.